Into This World We're Thrown
NCT05485038
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Other
Gender: All
Age: 18 Years to 69 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes:
Exclusions: Patients with prior radiation therapy to the brain
https://ClinicalTrials.gov/show/NCT05485038
NCT05489211
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Chemotherapy, Tyrosine-Kinase Inhibitor
Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have at least one target lesion that has not previously received radiation therapy
Exclusions: Patients with untreated brain metastases; Patients with leptomeningeal disease; Patients that have received prior treatment of a TROP2-directed antibody-drug conjugate (e.g. datopotamab deruxtecan , Trodelvy/sacituzumab govitecan) or other ADC with deruxtecan payload (e.g. Enhertu/Trastuzumab deruxtecan)
https://ClinicalTrials.gov/show/NCT05489211